Organon

FDA approved tapinarof (Vtama) cream 1% for atopic dermatitis in adults & children aged 2+; it's a steroid-free, once-daily treatment. The approval was based on the ADORING clinical program, showing significant improvement in disease clearance and itch reduction.

The FDA approved tapinarof cream, 1%, for treating atopic dermatitis in adults and children 2 years and older. In clinical trials, it significantly improved AD resolution compared to vehicle treatment, offering potential relief for young patients.

FDA approves VTAMA cream for atopic dermatitis in adults & children ≥2 years, showing efficacy, skin clearance, rapid itch relief, & safety in studies. Organon aims to address unmet needs in dermatitis treatment.

Organon's tapinarof cream, 1% (VTAMA), an aryl hydrocarbon receptor agonist, has been FDA-approved for treating atopic dermatitis in patients aged 2 years and up. It offers a steroid-free option, improving skin integrity and reducing itch, with significant efficacy observed in phase 3 trials.

FDA approves VTAMA® (tapinarof) cream, 1% for atopic dermatitis in adults & children ≥2 years. Studies show efficacy, skin clearance, rapid itch relief, & safety. Organon aims to address unmet needs in AD treatment.

Ally Schott's early endometriosis diagnosis at 12 led to limited treatment options and self-taught research. Despite its prevalence affecting 10% of women globally, endometriosis remains underfunded and poorly understood, with only two new drugs approved in the U.S. for pain management in the past decade. Women's health research generally suffers from insufficient funding and information deficits, hindering drug development. Recent federal efforts, including a $100 million investment by the Biden administration, aim to address these gaps, but future priorities under a new administration remain uncertain.

New denosumab biosimilar HLX14 nears FDA approval, supported by comparative studies. CT-P47 tocilizumab biosimilar shows similar safety and efficacy to reference in RA treatment. CT-P41 denosumab biosimilar demonstrates equivalent efficacy and safety in osteoporosis patients, with no impact of anti-drug antibody status on outcomes.

Women remain underrepresented in clinical trials, prompting the launch of Lindus Health's women's health-focused CRO. This CRO aims to address historical gaps by considering ethical and social factors, ensuring true informed consent, and developing strategies to overcome social barriers. Despite increased industry attention, diversity in clinical trials continues to suffer, with underrepresented groups like Black patients, elderly, disabled, indigenous, and transgender and nonbinary people lacking adequate representation. Boosting participation among these groups presents a market opportunity for sponsors.